# Molecular Partners AG: financial statements, quarterly

MOLN · Nasdaq · CIK 1745114 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/moln.md) · [Financials](/companies/moln/financials.md) · [Filings](/companies/moln/filings.md) · [Insiders](/companies/moln/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/moln/financials.md?period=annual).

## Balance sheet

| Line item | Unit | period not labelled (2018-12-31) | period not labelled (2019-12-31) | period not labelled (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [99.0](/filings/0001745114-22-000004.md) | [75.7](/filings/0001745114-23-000003.md) | [134](/filings/0001745114-24-000003.md) | [71.8](/filings/0001745114-25-000009.md) | [87.9](/filings/0001745114-26-000009.md) | [67.3](/filings/0001745114-26-000009.md) | [63.9](/filings/0001745114-26-000009.md) | [82.7](/filings/0001745114-26-000009.md) |
| Current assets | $m | not reported | not reported | [178](/filings/0001745114-22-000004.md) | [164](/filings/0001745114-23-000003.md) | [255](/filings/0001745114-24-000003.md) | [192](/filings/0001745114-25-000009.md) | [154](/filings/0001745114-26-000009.md) | [96.9](/filings/0001745114-26-000009.md) |
| Total assets | $m | not reported | not reported | [188](/filings/0001745114-22-000004.md) | [173](/filings/0001745114-23-000003.md) | [262](/filings/0001745114-24-000003.md) | [198](/filings/0001745114-25-000009.md) | [159](/filings/0001745114-26-000009.md) | [102](/filings/0001745114-26-000009.md) |
| Current liabilities | $m | not reported | not reported | [57.7](/filings/0001745114-22-000004.md) | [46.9](/filings/0001745114-23-000003.md) | [17.3](/filings/0001745114-24-000003.md) | [14.4](/filings/0001745114-25-000009.md) | [10.8](/filings/0001745114-26-000009.md) | [11.0](/filings/0001745114-26-000009.md) |
| Total liabilities | $m | not reported | not reported | [80.3](/filings/0001745114-22-000004.md) | [65.4](/filings/0001745114-23-000003.md) | [27.1](/filings/0001745114-24-000003.md) | [21.9](/filings/0001745114-25-000009.md) | [16.9](/filings/0001745114-26-000009.md) | [21.8](/filings/0001745114-26-000009.md) |
| Shareholders' equity | $m | [91.7](/filings/0001745114-22-000004.md) | [54.1](/filings/0001745114-23-000003.md) | [107](/filings/0001745114-24-000003.md) | [107](/filings/0001745114-25-000009.md) | [235](/filings/0001745114-26-000009.md) | [176](/filings/0001745114-26-000009.md) | [142](/filings/0001745114-26-000009.md) | [80.3](/filings/0001745114-26-000009.md) |

- Cash and equivalents: ifrs-full:CashAndCashEquivalents
- Current assets: ifrs-full:CurrentAssets
- Total assets: ifrs-full:Assets
- Current liabilities: ifrs-full:CurrentLiabilities
- Total liabilities: ifrs-full:Liabilities
- Shareholders' equity: ifrs-full:Equity

Shares outstanding: 40,374,641 at 2025-12-31, from the cover of the [20-F filed 2026-03-12](/filings/0001745114-26-000009.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.